

FORM PTO-1449

EIGHTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJH
FIRST NAMED INVENTOR
Ni et al.
FILING DATE
March 17, 1998APPLICATION NO.
09/042,583
ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
CU	AD1	2002/0098550	07/25/2002	Ni et al.	X	X	12/07/2001
	AE1	6,743,625	06/01/2004	Ni et al.			06/06/2001
	AF1	6,461,823	10/08/2002	Ni et al.			11/24/1999
	AG1	6,342,363	01/29/2002	Ni et al.			01/27/1998
CU	AH1	6,433,147	08/13/2002	Ni et al.			05/05/2000
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
CU	AN2	WO 98/41629 A2 & A3	09/24/1998	WIPO	X	X	Yes No
	AO2	EP 0 870 827 A2 & A3	10/14/1998	Europe			Yes No
CU	AP2	EP 1 181 319 A0	12/07/2000	Europe			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


CU	AR	9	Allison, J., et al., "Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts," <i>Proc. Natl. Acad. Sci. USA</i> 94:3943-3947, National Academy Press (April 1997)
	AS	9	Allison, J., and Strasser, A., "Mechanisms of β cell death in diabetes: A minor role for CD95," <i>Proc. Natl. Acad. Sci. USA</i> 95:13818-13822, National Academy Press (November 1998)
CU	AT	9	Bodmer, J.-L., et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88, Cell Press (January 1997)

EXAMINER

DATE CONSIDERED

8/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION NO.
09/042,583FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
March 17, 1998ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
Cur	AL3	EP 1 192 185 A0	12/14/2000	Europe			Yes No
Cur	AM3	EP 1 287 035 A1	03/05/2003	Europe			Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Cur	AR	10	Boldin, M.P., <i>et al.</i> , "A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain," <i>J. Biol. Chem.</i> 270:7795-7798, American Society for Biochemistry and Molecular Biology, Inc. (1995)
↓	AS	10	Chicheportiche, Y., <i>et al.</i> , "TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis," <i>J. Biol. Chem.</i> 272:32401-32410, American Society for Biochemistry and Molecular Biology, Inc. (December 1997)
Cur	AT	10	Chinnaiyan, A.M., <i>et al.</i> , "FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis," <i>Cell</i> 81:505-512, Cell Press (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

FIFTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION NO.
09/042,583FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
March 17, 1998ART UNIT
1646

Page 3 of 19

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL					Yes No
	AM					Yes No
	AN					Yes No
	AO					Yes No
	AP					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

aw	AR	11	Clerici, M., <i>et al.</i> , "Type 1 and Type 2 Cytokines in HIV Infection - A Possible Role in Apoptosis and Disease Progression," <i>Ann. Med.</i> 29:185-188, Finnish Medical Society DUODECIM (June 1997)
	AS	11	Degli-Esposti, M.A., <i>et al.</i> , "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> 186:1165-11170, Rockefeller University Press (October 1997)
aw	AT	11	Degli-Esposti, M.A., <i>et al.</i> , "The Novel Receptor TRAIL-R4 Induces NF- κ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain," <i>Immunity</i> 7:813-820, Cell Press (December 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION NO.
09/042,583FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
March 17, 1998ART UNIT
1646

Page 4 of 19

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>cu</i>	AR	<u>12</u>	Duan, H. and Dixit, V.M., "RAIDD is a new 'death' adaptor molecule," <i>Nature</i> 385:86-89, Macmillan Publishers, Ltd. (January 1997)
<i>cu</i>	AS	<u>12</u>	Frankfurt, O.S., <i>et al.</i> , "Protection from Apoptotic Cell Death by Interleukin-4 is Increased in Previously Treated Chronic Lymphocytic Leukemia Patients," <i>Leuk. Res.</i> 21:9-16, Elsevier Science, Ltd (January 1997)
<i>cu</i>	AT	<u>12</u>	Gooch, J.L., <i>et al.</i> , "Interleukin 4 Inhibits Growth and Induces Apoptosis in Human Breast Cancer Cells," <i>Cancer Res.</i> 58:4199-4205, American Association for Cancer Research (September 1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJH
FIRST NAMED INVENTOR
Ni *et al.*APPLICATION NO.
09/042,583FILING DATE
March 17, 1998ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>cu</i>	AR	13	Grell, M., <i>et al.</i> , "Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF," <i>EMBO J.</i> 18:3034-3043, Oxford University Press (June 1999)
	AS	13	Hardiman, G., <i>et al.</i> , "Genetic Structure and Chromosomal Mapping of MyD88," <i>Genomics</i> 45:332-339, Academic Press (October 1997)
<i>cu</i>	AT	13	Hildeman, D.A., <i>et al.</i> , "Activated T Cell Death In Vivo Mediated by Proapoptotic Bcl-2 Family Member Bim," <i>Immunity</i> 16:759-767, Cell Press (June 2002)

EXAMINER *Chen M. Kai*DATE CONSIDERED
8/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJH
FIRST NAMED INVENTOR
Ni et al.FILING DATE
March 17, 1998APPLICATION NO.
09/042,583ART UNIT
1646

Page 6 of 19

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	14	Hill, M.E., et al., "Prognostic Significance of BCL-2 Expression and bcl-2 Major Breakpoint Region Rearrangement in Diffuse Large Cell Non-Hodgkin's Lymphoma: A British National Lymphoma Investigation Study," <i>Blood</i> 88:1046-105, American Society of Hematology (August 1996)
AS	14	Hofmann, K., and Bucher, P., "The CARD domain: a new apoptotic signalling motif," <i>Trends Biochem. Sci.</i> 22:155-156, Elsevier Science, Ltd. (May 1997)
AT	14	Horigome, A., et al., "Tacrolimus-induced apoptosis and its prevention by interleukins in mitogen-activated human peripheral-blood mononuclear cells," <i>Immunopharmacology</i> 39:21-30, Elsevier Science B.V. (March 1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJH
FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
March 17, 1998APPLICATION NO.
09/042,583ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Ch	AR	15	Hsu, H., <i>et al.</i> , "TRADD-TRAF2 and TRADD-FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways," <i>Cell</i> 84:299-308, Cell Press (January 1996)
↑	AS	15	Huang, D.C.S., <i>et al.</i> , "Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x _L ," <i>Proc. Natl. Acad. Sci. USA</i> 96:14871-14876, National Academy Press (December 1999)
↓ Ar	AT	15	Huang, D.C.S., <i>et al.</i> , "Bcl-2, Bcl-x _L and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death," <i>Oncogene</i> 14:405-414, Stockton Press (January 1997)


EXAMINER

Chen M. G.

DATE CONSIDERED

8/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION NO.
09/042,583FIRST NAMED INVENTOR
Ni et al.FILING DATE
March 17, 1998ART UNIT
1646SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

cu	AR	16	Irmier, M., et al., "Direct physical interaction between the <i>Caenorhabditis elegans</i> 'death proteins' CED-3 and CED-4," <i>FEBS Lett.</i> 406:189-190, Elsevier Science B.V. (April 1997)
↑	AS	16	Irmier, M., et al., "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> 388:190-195, Macmillan Publishers, Ltd. (July 1997)
↓ an	AT	16	Karin, M., and Lin, A., "NF-κB at the crossroads of life and death," <i>Nat. Immunol.</i> 3:221-227, Nature Publishing Group (March 2002)

EXAMINER *Chen M. J.* DATE CONSIDERED *8/2/04*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

 <p>FORM PTO-1449</p>		Page 9 of 19		
		ATTY. DOCKET NO. 1488.1310002/EKS/EJH		APPLICATION NO. 09/042,583
		FIRST NAMED INVENTOR Ni et al.		
		FILING DATE March 17, 1998		ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes
							No
	AM						Yes
							No
	AN						Yes
							No
	AO						Yes
							No
	AP						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Ck	AR	17	Kelliher, M.A., et al., "The Death Domain Kinase RIP Mediates the TNF-Induced NF- κ B Signal," <i>Immunity</i> 8:297-303, Cell Press (March 1998)
↓	AS	17	Lindner, H., et al., "Peripheral Blood Mononuclear Cells Induce Programmed Cell Death in Human Endothelial Cells and May Prevent Repair: Role of Cytokines," <i>Blood</i> 89:1931-1938, American Society of Hematology (March 1997)
↓	AT	17	Lotem, J., and Sachs, L., "Hematopoietic Cytokines Inhibit Apoptosis Induced by Transforming Growth Factor β 1 and Cancer Chemotherapy Compounds in Myeloid Leukemic Cells," <i>Blood</i> 80:1750-1757, American Society of Hematology (1992)

EXAMINER <i>Chen</i>	DATE CONSIDERED 8/2/04
----------------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION NO.
09/042,583FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
March 17, 1998ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Cur ↓ an	AR	18	Lotem, J., and Sachs, L., "Interferon- γ inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells," <i>Leukemia</i> 9:685-692, Stockton Press (1995)				
	AS	18	MacFarlane, M., <i>et al.</i> , "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> 272:25417-25420, American Society for Biochemistry and Molecular Biology, Inc. (October 1997)				
	AT	18	Muzio, M., <i>et al.</i> , "FLICE, a Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex," <i>Cell</i> 85:817-827, Cell Press (June 1996)				


EXAMINER

Chen

DATE CONSIDERED

8/2/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJHFIRST NAMED INVENTOR
Ni *et al.*FILING DATE
March 17, 1998APPLICATION NO.
09/042,583ART UNIT
1646

Page 11 of 19

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	19	Muzio, M., <i>et al.</i> , "IRAK (Pelle) Family Member IRAK-2 and MyD88 as Proximal Mediators of IL-1 Signaling," <i>Science</i> 278:1612-1615, American Association for the Advancement of Science (November 1997)
AS	19	Newton, K., <i>et al.</i> , "A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes," <i>EMBO J.</i> 17:706-718, Oxford University Press (February 1998)
AT	19	Newton, K., <i>et al.</i> , "FADD/MORT1 regulates the pre-TCR checkpoint and can function as a tumour suppressor," <i>EMBO J.</i> 19:931-941, Oxford University Press (March 2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION NO.
09/042,583FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
March 17, 1998ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

an	AR	20	Newton, K., <i>et al.</i> , "Effects of a dominant interfering mutant of FADD on signal transduction in activated T cells," <i>Curr. Biol.</i> 11:273-276, Elsevier Science, Ltd. (February 2001)
↓	AS	20	Newton, K., and Strasser, A., "Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of Fas or FACC/MORT1 Signaling: Implications for Cancer Therapy," <i>J. Exp. Med.</i> 191:195-200, Rockefeller University Press (January 2000)
an	AT	20	O'Conner, L., and Strasser, A., "Fas, p53, and Apoptosis," <i>Science</i> 284:1431b, American Association for the Advancement of Science (May 1999)


EXAMINER

Chau M. Kay

DATE CONSIDERED

8/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJH
FIRST NAMED INVENTOR
Ni *et al.*APPLICATION NO.
09/042,583FILING DATE
March 17, 1998ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

an	AR	21	O'Conner, L., <i>et al.</i> , "CD95 (Fas/APO-1) and p53 Signal Apoptosis Independently in Diverse Cell Types," <i>Cancer Res.</i> 60:1217-1220, American Association for Cancer Research (March 2000)
↓	AS	21	Odaka, C., <i>et al.</i> , "Immunosuppressant deoxyspergualin induces apoptotic cell death in dividing cells," <i>Immunol.</i> 95:370-376, Blackwell Science, Ltd. (November 1998)
an	AT	21	Pan, G., <i>et al.</i> , "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," <i>FEBS Lett.</i> 424:41-45, Elsevier Science B.V. (March 1998)


EXAMINER

Chen M. G.

DATE CONSIDERED

8/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1488.1310002/EKS/EJH	APPLICATION NO. 09/042,583
FIRST NAMED INVENTOR Ni et al.	
FILING DATE March 17, 1998	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	22	Screaton, G.R., et al., "LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-4619, National Academy Press (April 1997)
	AS	22	Simonitsch, I., and Krupitza, G., "Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor α (TNF- α)," <i>Br. J. Cancer</i> 78:862-870, Nature Publishing Group on behalf of Cancer Research, UK (October 1998)
	AT	22	Smith, K.G.C., et al., "Crma expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphodenopathy or autoimmune disease," <i>EMBO J.</i> 15:5167-5176, Oxford University Press (October 1996)

EXAMINER 	DATE CONSIDERED 8/2/04
--------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION NO.
09/042,583FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
March 17, 1998ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

aw	AR	23	Strasser, A., <i>et al.</i> , "Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis," <i>EMBO J.</i> 14:6136-1647, Oxford University Press (1995)				
	AS	23	Thome, M., <i>et al.</i> , "Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors," <i>Nature</i> 386:517-521, Macmillan Publishers, Ltd. (April 1997)				
aw	AT	23	Villunger, A., <i>et al.</i> , "Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and p38 Mitogen-activated Protein Kinase: Regulators of Distinct Cell Death and Survival Pathways in Granulocytes," <i>J. Exp. Med.</i> 192:647-657, Rockefeller University Press (September 2000)				


EXAMINER

Clair M. King

DATE CONSIDERED

8/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION NO.
09/042,583FIRST NAMED INVENTOR
Ni et al.FILING DATE
March 17, 1998ART UNIT
1646SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

an	AR	24	Villunger, A., et al., "Fas Ligand-Induced c-Jun Kinase Activation in Lymphoid Cells Requires Extensive Receptor Aggregation But Is Independent of DAXX, and Fas-Mediated Cell Death Does Not Involve DAXX, RIP, or RAIDD," <i>J. Immunol.</i> 165:1337-1343, American Association of Immunologists (August 2000)
↓	AS	24	Walczak, H., et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> 16:5386-5397, Oxford University Press (September 1997).
an	AT	24	Watanabe-Fukunaga, R., et al., "Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis," <i>Nature</i> 356:314-317, Macmillan Publishers, Ltd. (1992)

EXAMINER *Chen Mr. K.* DATE CONSIDERED *8/2/04*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION NO.
09/042,583

Page 17 of 19

FIRST NAMED INVENTOR
Ni et al.FILING DATE
March 17, 1998ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>Chen</i>	AR	<u>25</u>	Wong, B.B., et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells," <i>J. Biol. Chem.</i> 272:25190-25194, American Society for Biochemistry and Molecular Biology, Inc. (October 1997)
<i>Chen</i>	AS	<u>25</u>	Yoshida, T., et al., "Rapid B cell apoptosis induced by antigen receptor ligation does not require Fas (CD95/APO-1), the adaptor protein FADD/MORT1 or CrmA-sensitive caspases but is defective in both MRL-+/+ and MRL-lpr/lpr mice," <i>Int. Immunol.</i> 12:517-526, Japanese Society for Immunology (April 2000)
<i>Chen</i>	AT	<u>25</u>	Zou, W., et al., "Administration of Interleukin 13 to Simian Immunodeficiency Virus-Infected Macaques: Induction of Intestinal Epithelial Atrophy," <i>AIDS Res Hum Retroviruses</i> 14:775-793, Mary Ann Liebert, Inc. (June 1998)


EXAMINER

Chen M. Kopf

DATE CONSIDERED

8/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

Page 18 of 19

ATTY. DOCKET NO.
1488.1310002/EKS/EJH
FIRST NAMED INVENTOR
Ni et al.APPLICATION NO.
09/042,583FILING DATE
March 17, 1998ART UNIT
1646SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Cur ↓ Cur	AR	26	European Search Report for European Application No. EP 00 93 0329 mailed on February 6, 2004, Munich, Germany				
	AS	26	Co-Pending U.S. Patent Application No. 09/565,009, Ni et al., filed May 4, 2000 (NOT PUBLISHED)				
	AT	26	Co-Pending U.S. Patent Application No. 10/005,842, Ni et al., filed December 7, 2001, now U.S. Published Patent Application No. 2002/0098550 (Document AD1)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJH
FIRST NAMED INVENTOR
Ni et al.
FILING DATE
March 17, 1998APPLICATION NO.
09/042,583
ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<input checked="" type="checkbox"/>	AR	27	Co-Pending U.S. Patent Application No. 10/648,825, Ni et al., filed August 27, 2003, now (NOT PUBLISHED) US Published Patent Application No. 2004/0136951.
<input checked="" type="checkbox"/>	AS	27	Co-Pending U.S. Patent Application No. 10/774,622, Ni et al., filed February 10, 2004, now (NOT PUBLISHED) US Published Patent Application No. 2004/0141952.
	AT		

EXAMINER

DATE CONSIDERED

8/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.